Tibet Weixinkang Medicine(603676)2024-09-30 09:29Group 1: Company Overview - The company, Tibet Weixin Kang Pharmaceutical Co., Ltd., is involved in the production and distribution of various pharmaceutical products [2]. - The company secretary, Yu Haibo, provided an introduction to the company's basic situation during the investor relations activity [2]. Group 2: Sales Performance - In the first half of 2024, the sales revenue of the injection of multiple vitamins (12) was 466 million yuan, showing a decline compared to the same period last year, despite an increase in sales volume [3]. - The sales revenue of the multi-trace element injection in the first half of 2024 was 57.63 million yuan, a decrease of 33.70% year-on-year [3]. - The sales revenue of the pediatric multi-vitamin injection (13) reached 32.75 million yuan in the first half of 2024, reflecting a growth of 47.29% year-on-year [4]. Group 3: Market Dynamics - The company has seen an increase in hospital coverage for the injection of multiple vitamins (12) post-collection, with both collection and non-collection areas experiencing sales growth [3]. - The pediatric multi-vitamin injection (13) is positioned as a unique product in the market, catering specifically to children under 11 years old, and has no direct competitors in the domestic market [4]. Group 4: Product Development and R&D - The company has completed market access for the pediatric compound amino acid injection (19AA-Ⅰ) in 31 provincial administrative regions and for the compound amino acid injection (20AA) in 29 regions [5]. - The company is actively pursuing new product development, with over 40 projects in the pipeline, including inhalation drugs and intravenous iron supplements [6]. - Recently, the company received clinical trial approval for deoxycholic acid injection, indicating ongoing innovation and product development efforts [6].